Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Associates in Hematology Oncology
mi
from
Chattanooga, TN
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Associates in Hematology Oncology
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Click here to add this to my saved trials
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated:  3/10/2016
Peninsula Cancer Institute
mi
from
Newport News, VA
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC)
Status: Enrolling
Updated: 3/10/2016
Peninsula Cancer Institute
mi
from
Newport News, VA
Click here to add this to my saved trials
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
A Phase I/II Study of the Combination of Pazopanib and Liposomal Doxorubicin (Doxil) in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Status: Enrolling
Updated:  3/11/2016
Florida Cancer Specialists
mi
from
Fort Myers, FL
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
A Phase I/II Study of the Combination of Pazopanib and Liposomal Doxorubicin (Doxil) in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Status: Enrolling
Updated: 3/11/2016
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
A Phase I/II Study of the Combination of Pazopanib and Liposomal Doxorubicin (Doxil) in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Status: Enrolling
Updated:  3/11/2016
Florida Hospital Cancer Insitute
mi
from
Orlando, FL
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
A Phase I/II Study of the Combination of Pazopanib and Liposomal Doxorubicin (Doxil) in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Status: Enrolling
Updated: 3/11/2016
Florida Hospital Cancer Insitute
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
A Phase I/II Study of the Combination of Pazopanib and Liposomal Doxorubicin (Doxil) in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Status: Enrolling
Updated:  3/11/2016
Oncology Hematology Care
mi
from
Cincinnati, OH
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
A Phase I/II Study of the Combination of Pazopanib and Liposomal Doxorubicin (Doxil) in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Status: Enrolling
Updated: 3/11/2016
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
A Phase I/II Study of the Combination of Pazopanib and Liposomal Doxorubicin (Doxil) in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Status: Enrolling
Updated:  3/11/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
A Phase I/II Study of the Combination of Pazopanib and Liposomal Doxorubicin (Doxil) in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Status: Enrolling
Updated: 3/11/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy
Phase I/II Evaluation of Cancer-Specific Imaging Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy
Status: Enrolling
Updated:  3/11/2016
St.Luke's-Roosevelt Hospital Center
mi
from
New York, NY
Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy
Phase I/II Evaluation of Cancer-Specific Imaging Using Ultrasound Spectrum Analysis (USA) to Guide Dose Escalated Prostate Brachytherapy
Status: Enrolling
Updated: 3/11/2016
St.Luke's-Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
Evaluation of Fosaprepitant's Effect on Drug Metabolism in Sarcoma Patients Receiving Ifosfamide-based Multi-day Chemotherapy Regimen
Status: Enrolling
Updated:  3/11/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
Evaluation of Fosaprepitant's Effect on Drug Metabolism in Sarcoma Patients Receiving Ifosfamide-based Multi-day Chemotherapy Regimen
Status: Enrolling
Updated: 3/11/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study
Status: Enrolling
Updated:  3/11/2016
Montefiore
mi
from
Bronx, NY
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study
Status: Enrolling
Updated: 3/11/2016
Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study
Status: Enrolling
Updated:  3/11/2016
Memorial Hospital
mi
from
Pawtucket, RI
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study
Status: Enrolling
Updated: 3/11/2016
Memorial Hospital
mi
from
Pawtucket, RI
Click here to add this to my saved trials
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study
Status: Enrolling
Updated:  3/11/2016
Rhode Island Hospital
mi
from
Providence, RI
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study
Status: Enrolling
Updated: 3/11/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study
Status: Enrolling
Updated:  3/11/2016
Miriam Hospital
mi
from
Providence, RI
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study
Status: Enrolling
Updated: 3/11/2016
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study
BrUOG 278:FOLFOX-A For Pancreatic Cancer :A Brown University Oncology Research Group Study
Status: Enrolling
Updated:  3/11/2016
Memorial Hospital
mi
from
Pawtucket, RI
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study
BrUOG 278:FOLFOX-A For Pancreatic Cancer :A Brown University Oncology Research Group Study
Status: Enrolling
Updated: 3/11/2016
Memorial Hospital
mi
from
Pawtucket, RI
Click here to add this to my saved trials
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study
BrUOG 278:FOLFOX-A For Pancreatic Cancer :A Brown University Oncology Research Group Study
Status: Enrolling
Updated:  3/11/2016
Rhode Island Hospital (including Newport and East Greenwich locations)
mi
from
Providence, RI
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study
BrUOG 278:FOLFOX-A For Pancreatic Cancer :A Brown University Oncology Research Group Study
Status: Enrolling
Updated: 3/11/2016
Rhode Island Hospital (including Newport and East Greenwich locations)
mi
from
Providence, RI
Click here to add this to my saved trials
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study
BrUOG 278:FOLFOX-A For Pancreatic Cancer :A Brown University Oncology Research Group Study
Status: Enrolling
Updated:  3/11/2016
Miriam Hospital
mi
from
Providence, RI
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study
BrUOG 278:FOLFOX-A For Pancreatic Cancer :A Brown University Oncology Research Group Study
Status: Enrolling
Updated: 3/11/2016
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  3/11/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 3/11/2016
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  3/11/2016
Duke Cancer Institute
mi
from
Durham, NC
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 3/11/2016
Duke Cancer Institute
mi
from
Durham, NC
Click here to add this to my saved trials
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  3/11/2016
Gabrail Cancer Center
mi
from
Canton, OH
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 3/11/2016
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  3/11/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 3/11/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  3/11/2016
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 3/11/2016
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Click here to add this to my saved trials
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated:  3/11/2016
Institut Gustave Roussy
mi
from
Paris,
Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Hepatic Impairment
An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment
Status: Enrolling
Updated: 3/11/2016
Institut Gustave Roussy
mi
from
Paris,
Click here to add this to my saved trials
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Phase I/II Study Of Herceptin Combined With OSI-774 In The First-Line Treatment Of Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Status: Enrolling
Updated:  3/11/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Phase I/II Study Of Herceptin Combined With OSI-774 In The First-Line Treatment Of Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Status: Enrolling
Updated: 3/11/2016
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Outlook Quality of Life Intervention
Outlook: An Intervention to Improve Quality of Life in Serious Illness
Status: Enrolling
Updated:  3/11/2016
Durham VA Medical Center HSR&D COE
mi
from
Durham, NC
Outlook Quality of Life Intervention
Outlook: An Intervention to Improve Quality of Life in Serious Illness
Status: Enrolling
Updated: 3/11/2016
Durham VA Medical Center HSR&D COE
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy of Morning-only Bowel Preparation for Afternoon Colonoscopy.
A Randomized Endoscopist-blinded Clinical Trial Comparing the Bowel Cleansing Effect and Patient Tolerability of Same Day Polyethylene Glycol Bowel Preparation Regimen v Regimen Given on the Day Before Colonoscopy
Status: Enrolling
Updated:  3/11/2016
Cleveland Clinic Florida
mi
from
Weston, FL
Efficacy of Morning-only Bowel Preparation for Afternoon Colonoscopy.
A Randomized Endoscopist-blinded Clinical Trial Comparing the Bowel Cleansing Effect and Patient Tolerability of Same Day Polyethylene Glycol Bowel Preparation Regimen v Regimen Given on the Day Before Colonoscopy
Status: Enrolling
Updated: 3/11/2016
Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials
Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer
A Feasibility Study of Re-irradiation Using Stereotactic Body Radiation Therapy (SBRT) and Cetuximab for Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Enrolling
Updated:  3/14/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer
A Feasibility Study of Re-irradiation Using Stereotactic Body Radiation Therapy (SBRT) and Cetuximab for Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status: Enrolling
Updated: 3/14/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Dana-Farber Cancer Center
mi
from
Boston, MA
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Dana-Farber Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Karmanos Cancer Center
mi
from
Detroit, MI
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Karmanos Cancer Center
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer
Status: Enrolling
Updated:  3/14/2016
University of Indiana
mi
from
Indianapolis, IN
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer
Status: Enrolling
Updated: 3/14/2016
University of Indiana
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Washington University
mi
from
St. Louis, MO
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer
Status: Enrolling
Updated:  3/14/2016
University of California at San Francisco
mi
from
San Francisco, CA
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, and Pharmacokinetic Clinical Study of Intravenously Administered MM-302 Monotherapy and in Combination With Trastuzumab With or Without Cyclophosphamide in Patients With Advanced HER2 Positive Breast Cancer
Status: Enrolling
Updated: 3/14/2016
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Combination of Cilengitide and Paclitaxel in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  3/14/2016
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Combination of Cilengitide and Paclitaxel in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 3/14/2016
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Combination of Cilengitide and Paclitaxel in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  3/14/2016
Mayo Clinic Florida
mi
from
Jacksonville, FL
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Combination of Cilengitide and Paclitaxel in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 3/14/2016
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Combination of Cilengitide and Paclitaxel in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  3/14/2016
The Mayo Clinic
mi
from
Rochester, MN
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetic Properties of the Combination of Cilengitide and Paclitaxel in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 3/14/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer
Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer: A Randomized Trial
Status: Enrolling
Updated:  3/14/2016
Massachusetts General Hospital
mi
from
Boston, MA
Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer
Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer: A Randomized Trial
Status: Enrolling
Updated: 3/14/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Breastlink Med Group Inc
mi
from
Long Beach, CA
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Breastlink Med Group Inc
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Georgia Cancer Specialists
mi
from
Atlanta, GA
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Georgia Cancer Specialists
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Montana Cancer Institute Foundation
mi
from
Missoula, MT
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Montana Cancer Institute Foundation
mi
from
Missoula, MT
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Oncology Hematology Care
mi
from
Cincinnati, OH
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Guthrie Clinic, Ltd.
mi
from
Sayre, PA
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Guthrie Clinic, Ltd.
mi
from
Sayre, PA
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Santee Hematology Oncology, Inc.
mi
from
Sumter, SC
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Santee Hematology Oncology, Inc.
mi
from
Sumter, SC
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
University of Alabama at Birmingham, Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
Arizona Cancer Center
mi
from
Tucson, AZ
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated:  3/14/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
A Phase II, Randomized, Multicenter Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
Status: Enrolling
Updated: 3/14/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials